Allion has acted for the Lions Eye Institute, a not-for-profit medical research institution, on the launch of its commercial collaboration with Phylogica Limited (ASX: PYC), via formation of a new subsidiary, Vision Pharma. Phylogica, trading as PYC Therapeutics, has been listed on the ASX since 2005.

The collaboration will involve the development and commercialisation of precision medicines and treatment for the leading cause of childhood blindness with a new Australian-developed drug delivery platform. With no existing treatment options available for the disease, it is thought the therapy’s potential target market could top $1 billion per year.